Clinical trials: Plasmapheresis
COVID-19
Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis
Introduction: The SARS-CoV-2 outbreak has left more than two million infected worldwide in the first four months of COVID-19 epidemic.
- Trial name
- PLASMA (NCT04480632)
- Testing
- Convalescent plasma
- Where
- Colombia
- Volunteers
- 44 people
- Sponsor
- Fundación Cardiovascular de Colombia
Septic Shock
Therapeutic Plasmaexchange in Early Septic Shock
Sepsis is defined by the occurrence of critical organ dysfunction in the context of infection. Unfortunately, its incidence appears to be rising, and the mortality of septic shock remains extraordinary high (> 60%).
- Trial name
- EXCHANGE (NCT04231994)
- Testing
- TPE
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Hannover Medical School
Acute-On-Chronic Liver Failure
Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%
This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects.
- Trial name
- APACHE (NCT03702920)
- Testing
- SMT + PE-A 5%, Standard Medical Treatment
- Where
- 30 sites in United States, Austria and 7 more
- Volunteers
- 274 people
- Sponsor
- Instituto Grifols, S.A.
COVID19
Study of Plasma Exchange in Severe COVID-19
The rationale in severe COVID19 infection is to undertake PEX to aid reduction of the hyperinflammation and reduce the morbidity and mortality to the lungs, but also systemically, such as the heart, kidneys and brain.
- Trial name
- COVIPLEX (NCT04623255)
- Testing
- OCTAPLAS
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University College, London
Idiopathic Pulmonary Fibrosis
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for…
- Trial name
- STRIVE II (NCT07674745)
- Testing
- Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Alabama at Birmingham
Wegener's Granulomatosis, Microscopic Polyangiitis
Plasma Exchange for Renal Vasculitis
The purpose of this study is to test whether additional therapy with plasma exchange improves the chances of kidney recovery in severe kidney vasculitis.
- Trial name
- MEPEX (NCT01408836)
- Testing
- Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Focal Segmental Glomerulosclerosis, Guillain-Barre Syndrome
Regional Citrate Anticoagulation in Plasma Exchange Treatment
The investigators want to compare the efficacy of plasma exchange treatment with using two different citrates ( 4% and 15% ) as anticoagulants in plasma exchange treatment.
- Trial name
- NCT01370200
- Testing
- plasma exchange treatment
- Where
- Slovenia
- Volunteers
- 140 people
- Sponsor
- University Medical Centre Ljubljana
Guillain-Barre Syndrome
IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients
In this study, the investigators address the question: whether treatment with IVIG is superior to treatment using plasmapheresis for functional recovery of patients with GBS? Recovery was quantified using: The changes in the…
- Trial name
- NCT05104762
- Testing
- plasmapheresis device, Intravenous immunoglobulin
- Where
- Egypt
- Volunteers
- 81 people
- Sponsor
- Assiut University
Antibody-mediated Rejection, Kidney Transplant Rejection
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Antibody-mediated rejection (ABMR) is one of the leading causes of graft loss in kidney transplant recipients (KTRs). Although it is a well characterized entity, there is limited data regarding effective treatment options for…
- Conditions
- Antibody-mediated Rejection, Kidney Transplant Rejection, Graft Loss
- Trial name
- NCT04367610
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Istanbul University
Severe Acute Respiratory Syndrome, SARS
Collection of Convalescent SARS Plasma by Apheresis
The purpose of this study is to collect plasma by apheresis from patients who have recovered from Severe Acute Respiratory Syndrome (SARS).
- Trial name
- NCT00342524
- Where
- China
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Microplastic and Nanoplastic Particle Burden in Peripheral Blood, Double-Filtration Plasmapheresis
Evaluating DFPP for Microplastic and PFAS Reduction
This prospective, non-interventional, within-subject paired biomarker study will evaluate whether circulating microplastic and nanoplastic-associated particle concentrations and PFAS concentrations in peripheral blood change…
- Trial name
- DFPP-MNP (NCT07658443)
- Testing
- Double-Filtration Plasmapheresis With the IN300 Apheresis Device
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 20 people
- Sponsor
- Proxima Health, Inc.
High Titers of Anti-HLA Antibody (MFI ≥5000)
The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT
Evaluation of the efficacy and safety of immunoadsorption or plasma exchange combined with rituximab and high-dose IVIG to reduce high titres of anti-HLA antibodies in patients prior to allogeneic haematopoietic stem cell…
- Trial name
- NCT06362967
- Testing
- Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Hospital
Optic Neuritis
Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis
Patients aged between 18 and 70 with acute aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) positive optic neuritis, irrespective of prior using of corticosteroids in this episode of disease, are chosen by the physician.
- Trial name
- NCT03586557
- Testing
- Corticosteroid & Plasma exchange, Corticosteroid
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Chinese PLA General Hospital
Myasthenia Gravis
Therapeutic Plasma Exchange in MG
The primary objective of the study is to longitudinally profile immunoglobulin levels and autoantibody levels in subjects with myasthenia gravis (MG) who receive therapeutic plasma exchange (TPE).
- Trial name
- TPE (NCT01927692)
- Testing
- Skin biopsy, Single Fiber Electromyography
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Myasthenia Gravid
Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis
Immunomodulation is effective in treating patients with myasthenia gravis (MG), but prior studies have not adequately defined if plasma exchange (PLEX) in superior to intravenous immunoglobulin (IVIG) in the treatment of…
- Trial name
- NCT01179893
- Testing
- IVIG, PLEX
- Where
- Canada
- Volunteers
- 87 people
- Sponsor
- University Health Network, Toronto
Thrombotic Thrombocytopenic Purpura
Octaplas Adult TTP Trial
To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in…
- Trial name
- NCT01938404
- Testing
- Octaplas, Standard Plasma
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Octapharma
Autoimmune Encephalitis (AE)
Plasma Exchange in Pediatric Autoimmune Encephalitis
The aim of the study will be to compare the efficacy of daily plasma exchange (PLEX) versus alternate-day PLEX in achieving a favorable functional outcome in children with autoimmune encephalitis.
- Trial name
- PE/AIE (NCT07707739)
- Testing
- Plasma exchange (PE)
- Where
- Egypt
- Volunteers
- 22 people
- Sponsor
- Menoufia University
Immunology
ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration
Recipient desensitization protocols were shown to enable successful living donor kidney transplantation across major ABO blood group barriers.
- Trial name
- NCT01698736
- Testing
- Membrane filtration, Semiselective IA
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Medical University of Vienna
Aluminium Phosphide Poisoning
CRRT Versus Plasmapheresis in Aluminum Phosphide Poisoning
Aluminum phosphide (AlP) is a solid fumigant pesticide sold as tablets in use since the 1940s. It is considered to be an ideal pesticide because of its cheapness, efficiency, and easy availability in the market and is widely used…
- Trial name
- AlP (NCT05334667)
- Testing
- Routine management, CRRT, PPH
- Volunteers
- 75 people
- Sponsor
- Assiut University
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Acute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks.
- Trial name
- STRIVE-IPF (NCT03286556)
- Testing
- Autoantibody Reductive Therapy, Treatment as Usual (TAU)
- Where
- 7 sites in United States
- Volunteers
- 82 people
- Sponsor
- University of Alabama at Birmingham